Critical care and hospital survival according to patient group and intensive care unit (ICU) therapy
N | ICU survival | Hospital survival | 90-day survival | 1-year survival | N# | 5-year survival# | |
Overall | 242 | 190 (78.5) | 169 (69.8) | 158 (65.3) | 132 (54.5) | 146 | 45 (30.8) |
Patient group | |||||||
Medical | 167 | 120 (71.9) | 99 (59.3) | 91 (54.5) | 68 (40.7) | 114 | 26 (22.8) |
Surgical | 50 | 47 (94.0) | 47 (94.0) | 45 (90) | 42 (84) | 19 | 10 (52.6) |
Obstetric | 25 | 23 (92.0) | 23 (92.0) | 22 (88) | 22 (88) | 13 | 9 (69.2) |
PH group | |||||||
1 PAH | 162 | 127 (78.4) | 115 (71.0) | 107 (66.0) | 90 (55.6) | 95 | 32 (33.7) |
2 PH due to left heart disease | 13 | 11 (84.6) | 10 (76.9) | 10 (76.9) | 8 (61.5) | 7 | 2 (28.6) |
3 PH due to lung disease/hypoxia | 14 | 9 (64.3) | 8 (57.1) | 7 (50) | 6 (42.9) | 10 | 0 (0) |
4 Chronic thromboembolic PH | 39 | 34 (87.2) | 29 (74.4) | 27 (69.2) | 24 (61.5) | 26 | 10 (38.5) |
5 Unclear/multifactorial | 14 | 9 (64.3) | 7 (50) | 7 (50) | 4 (28.6) | 8 | 1 (12.5) |
ICU therapy (medical patients only) | |||||||
CPAP as highest level of ventilatory support | 53 | 34 (64.1) | 27 (50.9) | 25 (47.1) | 20 (37.7) | 33 | 2 (6.1) |
NPPV as highest level of ventilatory support | 15 | 9 (60) | 6 (40) | 5 (33.3) | 3 (20) | 10 | 0 (0) |
IPPV as highest level of ventilatory support | 9 | 3 (33.3) | 1 (11.1) | 1 (11.1) | 1 (11.1) | 9 | 0 (0) |
CRRT | 22 | 17 (77.3) | 11 (50.0) | 9 (40.9) | 7 (31.8) | 20 | 5 (25) |
Vasopressors received | 49 | 23 (46.9) | 16 (32.7) | 15 (30.6) | 11 (22.4) | 28 | 3 (10.7) |
Inotropes received | 37 | 17 (45.9) | 13 (35.1) | 12 (32.4) | 7 (18.9) | 29 | 3 (10.3) |
Prostaglandins (intravenous) received | 113 | 78 (69.0) | 68 (60.2) | 61 (54) | 45 (39.8) | 73 | 18 (24.7) |
Data are presented as n (%), unless otherwise stated. PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; CPAP: continuous positive airway pressure; NPPV: non-invasive positive pressure ventilation: IPPV: invasive positive pressure ventilation; CRRT: continuous renal replacement therapy. #: patients admitted prior to 31 December 2013 for whom 5 years of survival data is available.